NCT05910177View on ClinicalTrials.gov

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 28, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
CarcinomaCervix Carcinoma
Interventions
DRUG

Karelizumab combined with etoposide and cisplatin

Karelizumab：200 mg，ivgtt，D1，q3w； Cisplatin：75 mg/m2，ivgtt，D1，q3w； Etoposide：100 mg/m2，ivgtt，D1\~3，q3w

Trial Locations (1)

350014

RECRUITING

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV